alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
United States Court of Appeals

FOR THE EIGHTH CIRCUIT

_____________

No. 96-2175WM

_____________

David Duvall, *

*

Appellant, * Appeal from the United States

* District Court for the Western

v. * District of Missouri.

*

Jeffrey Elnicki; Karen Misjak; * [UNPUBLISHED]

John Doe, 1 thru 5, *

*

Appellees. *

_____________

Submitted: February 7, 1997

 Filed: February 21, 1997

_____________

Before McMILLIAN, FAGG, and LOKEN, Circuit Judges.

_____________

PER CURIAM.

In this 42 U.S.C. § 1983 action, David Duvall claimed that

Jeffrey Elnicki and Karen Misjak conspired to violated Duvall's

First Amendment rights by refusing to service his student loan and

denying him access to public records under the control of the

Missouri Coordinating Board for Higher Education (CBHE), in

retaliation for his filing a state-court lawsuit against the CBHE.

Duvall contends the district court improperly granted Elnicki's and

Misjak's summary judgment motions. Having carefully reviewed the

record, we conclude the district court correctly ruled that Elnicki

was absolutely immune from suit for his advocacy functions as a

state assistant attorney general and that Misjak and Elnicki (to

the extent Duvall's claims did not involve Elnicki's advocacy

functions) were entitled to summary judgment on qualified immunity

grounds. We also agree with the district court that Duvall's

conspiracy allegations are conclusory and insufficient to establish
-2-

a meeting of the minds on the part of Elnicki and Misjak to violate

Duvall's constitutional rights. Finally, contrary to Duvall's

view, the district court implicitly denied Duvall's motion for

additional discovery under Federal Rule of Civil Procedure 56(f)

and did not abuse its discretion in making the ruling. We thus

affirm the district court. See 8th Cir. R. 47B.

A true copy.

Attest:

CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
Summary of Non-Employee Director Compensation of Registrant



 Exhibit 10.11 
 SUMMARY OF NON-EMPLOYEE DIRECTOR COMPENSATION 
 Cash Compensation 
 The non-employee directors of Kadant Inc. (the “company”) are paid the following cash meeting and retainer fees for serving on its board of
directors: 
  

	 	•	 	 An annual retainer fee of $18,000, payable in monthly installments of $1,500 each. 


  

	 	•	 	 A meeting fee of $1,500 for attending regular meetings of the board of directors in person and $750 for participating in meetings held by telephone in which
substantive action is taken or that last more than one hour. 


  

	 	•	 	 A meeting fee of $500 for attending regularly scheduled committee meetings of the board of directors in person and $250 for participating in committee meetings held
by telephone in which substantive action is taken or that last more than one hour. 


  

	 	•	 	 An annual retainer for chairmen of the following committees: audit committee - $3,000; compensation committee - $2,000; nominating and corporate governance
committee - $1,000. 


  

	 	•	 	 Reimbursement of out-of pocket expenses incurred in attending or participating in meetings of the board of directors or its committees.



 Restricted Stock 
 Prior to 2008, non-employee directors of the company also received an award of 15,000 restricted shares of common stock annually pursuant to an award made in the first quarter of the fiscal year. Beginning in 2008, this award was structured
as an award of restricted stock units (RSUs). The restricted shares (or RSUs) vest as follows: installments of 1,250 restricted shares (or RSUs) each vest on the last day of each of the company’s fiscal quarters during the year and the
remaining 10,000 restricted shares (or RSUs) vest only in the event that a change-in-control of the company occurs or is approved during the period beginning on the first day of the second quarter of the current fiscal year and ending on the last
day of the first quarter of the following fiscal year. The restricted shares (or RSUs) are forfeited if the individual is no longer a member of the board of directors on the vesting dates. The vesting on all of the restricted shares (or RSUs)
accelerate in the event of a change-in-control of the company. All awards are made under the company’s shareholder-approved equity incentive plans. The terms and conditions governing these awards are stated in the form of restricted stock
agreement for non-employee directors and form of restricted stock unit award agreement for non-employee directors filed as exhibits to the company’s annual report on Form 10-K. 
 Stock Options 
 Stock options may be granted periodically to non-employee directors under the
company’s shareholder-approved equity incentive plans. The size and the terms of any grant are determined by the compensation committee of the board of directors. In all 








 
cases, the exercise price of the option is determined at fair market value on the date of grant. Generally, options are exercisable and vest in three annual
installments on the first three anniversaries of the date of grant, and the option expires seven years from the date of grant.
II 

112TH CONGRESS 

2D SESSION S. 3000 

To extend the temporary suspension of duty on allyl isosulfocynate. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on allyl 

isosulfocynate. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ALLYL ISOSULFOCYNATE. 

4 (a) IN GENERAL.—Heading 9902.01.41 of the Har5 monized Tariff Schedule of the United States (relating to 

6 allyl isothiocyanate) is amended by striking the date in 

7 the effective period column and inserting ‘‘12/31/2015’’. 

8 (b) EFFECTIVE DATE.—The amendment made by 

9 subsection (a) applies with respect to goods entered, or 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 3000 IS

1 withdrawn from warehouse for consumption, on or after 

2 the 15th day after the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS
CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report of Cardero Resource Corp. (the Company) on Form 40-F for the year ended October 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Michael W. Kinley, the Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



3.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

4.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:  January 29, 2008



/s/ Michael W. Kinley

Michael W. Kinley
Chief Financial Officer
[Federal Register Volume 74, Number 75 (Tuesday, April 21, 2009)]
[Notices]
[Page 18199]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-9119]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration

[A-552-801]


Certain Frozen Fish Fillets from the Socialist Republic of 
Vietnam: Extension of Time Limit for Final Results of the Third New 
Shipper Review

AGENCY: Import Administration, International Trade Administration, 
Department of Commerce


DATES: Effective Date: April 20, 2009.

FOR FURTHER INFORMATION CONTACT: Alan Ray, AD/CVD Operations, Office 9, 
and Emeka Chukwudebe, AD/CVD Operations, Office 9, Import 
Administration, International Trade Administration, U.S. Department of 
Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 
20230; telephone: (202) 482-5403 and (202) 482-0219, respectively.

Background

    On January 28, 2009, the Department of Commerce (``Department'') 
published the preliminary results of the third new shipper review for 
the period August 1, 2007, through January 31, 2008. See Certain Frozen 
Fish Fillets From the Socialist Republic of Vietnam: Notice of 
Preliminary Results of the Third New Shipper Review, 74 FR 4920 
(January 28, 2009) (``Preliminary Results''). The final results are 
currently due on April 16, 2009.

Extension of Time Limits for Final Results

    Section 751(a)(2)(B)(iv) of the Tariff Act of 1930, as amended 
(``Act''), and 19 CFR 351.214(i)(1) require the Department to issue the 
final results in a new shipper review of an antidumping duty order 90 
days after the date on which the preliminary results are issued. The 
Department may, however, extend the deadline for completion of the 
final results of a new shipper review to 150 days if it determines that 
the case is extraordinarily complicated. See section 751(a)(2)(B)(iv) 
of the Act and 19 CFR 351.214(i)(2).
    The Department finds this case is extraordinarily complicated 
because a study recently placed on the record presents a number of 
complex factual and legal questions with regard to the surrogate value 
of whole fish. Therefore, the Department and interested parties need 
more time to analyze the study. Accordingly, because the Department 
requires additional time to complete the final results, we are 
extending the time for the completion of the final results of this 
review by 60 days to June 15, 2009.
    This notice is published in accordance with section 
751(a)(2)(B)(iv) of the Act and 19 CFR 351.214(i)(2).

    Dated: April 15, 2009.
John M. Andersen,
Acting Deputy Assistant Secretary for Antidumping and Countervailing 
Duty Operations.
[FR Doc. E9-9119 Filed 4-20-09; 8:45 am]
BILLING CODE 3510-DS-P
Assessing Health Risks in Consumer 

Products

Treye A. Thomas, Ph.D.

Directorate for Health Sciences

Office of Hazard Identification and Reduction

U.S. Consumer Product Safety Commission 

The views expressed in this presentation are those of the CPSC staff, have not been reviewed or approved by, and may not 

necessarily reflect the views of the Commission.
Who is CPSC?

• The U.S. Consumer Product Safety Commission is an 

independent regulatory agency created in 1973.

• Mission: To protect the public from unreasonable risk of 

injury and death associated with consumer products.

• Jurisdiction includes thousands of different types of 

products sold to consumers for personal use in or 

around the household or school and in recreation.

– Toys, electronic equipment, appliances, clothing/textiles, 

household cleaners/chemicals, and building materials
Regulatory Authority

• Consumer Product Safety Act (CPSA),

15 U.S.C. § 2051-2084

• Federal Hazardous Substances Act 

(FHSA), 

15 U.S.C. § 1261-1278

• Consumer Product Safety Improvement 

Act of 2008 (CPSIA)
Definitions of Toxicity

• CPSC regulates many chemical hazards under the 

Federal Hazardous Substances Act (FHSA) (15 U.S.C. 

§§ 1261-1278)

• Under the FHSA, the term "hazardous substance" is 

defined as: 

“Any substance or mixture of substances which (i) is 

toxic, (ii) is corrosive, (iii) is an irritant, (iv) is a strong 

sensitizer, (v) is flammable or combustible, or (vi) 

generates pressure through decomposition, heat, or 

other means, if such substance or mixture of substances 

may cause substantial personal injury or substantial 

illness during or as a proximate result of any customary 

or reasonably foreseeable handling or use, including 

reasonably foreseeable ingestion by children." 
Federal Hazardous Substances Act

• Risk-based

• Includes acute and chronic effects 

• Reliable human data preferred

• Does not require pre require pre-market approval market approval

• Manufacturers ensure that their products are not 

hazardous & are properly labeled

• Hazardous children’s products are banned

• Manufacturers must report “substantial product 

hazards” (CPSA)
Risk Assessment Paradigm

• Hazard Identification

– Is it toxic?

• Dose Response Assessment

– How toxic is it? 

– What is the acceptable daily intake (ADI)?

• Exposure Assessment

– How much contacts your body?

• Risk Characterization

– Does the intake exceed the ADI?
Chronic Hazard Guidelines (CHG)

• In 1992, the Commission issued guidelines for assessing 

chronic hazards under the FHSA

• Provides guidance on 

– Determining toxicity (e.g., carcinogenicity, neurotoxicity, 

bioavailability) 

– Acceptable Daily Intake (ADI) 

– Threshold for uptake into body

– Assessing exposure 

– Risk assessment approaches and acceptable risk

• Intended to assist manufacturers in complying with the FHSA 
Options

• Labeling

• Product Recalls 

• Product Bans

• Voluntary Standards 

• Mandatory Standards

• Other
Contact Information

CPSC Website - www.cpsc.gov

Questions - tthomas@cpsc.gov
II 

112TH CONGRESS 

2D SESSION S. 2992 

To extend the temporary suspension of duty on 1-propene, 1,1,2,3,3,3- 

hexafluoro-, oxidized, polymerized, reduced hydrolyzed. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on 1-propene, 

1,1,2,3,3,3-hexafluoro-, oxidized, polymerized, reduced 

hydrolyzed. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 1-PROPENE, 1,1,2,3,3,3-HEXAFLUORO-, OXIDIZED, 

4 POLYMERIZED, REDUCED HYDROLYZED. 

5 (a) IN GENERAL.—Heading 9902.23.10 of the Har6 monized Tariff Schedule of the United States (relating to 

7 1-propene, 1,1,2,3,3,3-hexafluoro-, oxidized, polymerized, 

8 reduced hydrolyzed) is amended by striking the date in 

9 the effective period column and inserting ‘‘12/31/2015’’. 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 2992 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS
<TABLE> <S> <C>

<ARTICLE>                     5
<CIK>                         0000755872
<NAME>                        KFP 85-LTD.
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                   DEC-31-1997
<PERIOD-END>                        SEP-30-1998
<CASH>                                  191,366
<SECURITIES>                                  0
<RECEIVABLES>                            60,056
<ALLOWANCES>                            (44,730)
<INVENTORY>                                   0
<CURRENT-ASSETS>                              0
<PP&E>                                5,546,523
<DEPRECIATION>                       (2,199,938)
<TOTAL-ASSETS>                        4,670,505
<CURRENT-LIABILITIES>                         0
<BONDS>                               4,401,098
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<COMMON>                                      0
<OTHER-SE>                               22,109
<TOTAL-LIABILITY-AND-EQUITY>          4,670,505
<SALES>                                       0
<TOTAL-REVENUES>                        654,695
<CGS>                                         0
<TOTAL-COSTS>                                 0
<OTHER-EXPENSES>                        511,146
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                      346,514
<INCOME-PRETAX>                        (202,965)
<INCOME-TAX>                                  0
<INCOME-CONTINUING>                    (202,965)
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                           (202,965)
<EPS-PRIMARY>                            (25.05)
<EPS-DILUTED>                            (25.05)
        
<FN>
NOTE: TOTAL CURRENT ASSETS AND TOTAL CURRENT LIABILITIES ARE NOT APPLICABLE
BECAUSE REGISTRANT DOES NOT PRESENT A CLASSIFIED BALANCE SHEET.
</FN>

</TABLE>
ex105.htm



Exhibit 10.05  





 


 


December 9, 2010










Lederman & Co., LLC










245 E. 93rd St. 14E


New York, NY 10022


Attn: Seth Lederman, Managing Member












Re:  Consulting Agreement







Dear Dr. Lederman:







Reference is made to the Consulting Agreement (the “Consulting Agreement”) dated as of June 4, 2010 between Lederman & Co., LLC (“Lederman & Co.”) and Tonix Pharmaceuticals, Inc. (“Tonix”).  Lederman & Co. hereby agrees that the definition of the term IPO for purposes of the Consulting Agreement shall be amended and restated in its entirety to be:







the closing of the sale of shares of the common stock of the Company to the public in an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $15,000,000 of proceeds, net of the underwriting discount and commissions, to the Company







Except as expressly provided herein, the terms and conditions of the Consulting Agreement remain in full force and effect.  Please confirm Lederman & Co.’s acknowledgement and acceptance of the terms hereof by returning a signed copy of this letter to me.









	 	 	 
	 	 	 	 
	
 

	
By: 

	/s/ SUSAN F. OLIVER	 
	 	 	Name:  Susan F. Oliver	 
	 	 	Title:  Secretary	 
	 	 	 	 
	 	 	 	 
	 	 	on behalf of Tonix Pharmaceuticals, Inc.	 















 












Acknowledged and Accepted







LEDERMAN & CO., LLC







By: /s/ SETH LEDERMAN


Name:  Seth Lederman


Title:  Managing Member




 


 


 


 


 


 


 


 


 


 



2 Park 80 Plaza West – Suite 200, 250 Pehle Avenue, Saddle Brook, NJ 07663


Tel: 201.291.2642 • Fax: 212.923.5700
II 

112TH CONGRESS 

2D SESSION S. 2974 

To suspend temporarily the duty on 3–Methylylbenzyl Chloride. 

IN THE SENATE OF THE UNITED STATES 

MAY 8, 2012 

Mr. MENENDEZ introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To suspend temporarily the duty on 3–Methylylbenzyl 

Chloride. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. 3–METHYLYLBENZYL CHLORIDE. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 

‘‘ 9902.01.00 Methylylbenzyl Chloride 

(CAS No. 620–19–9) (provided for in subheading 

2903.69.8000) ....................... Free No change No change On or before 

12/31/2015 ’’. 


srobinson on DSK4SPTVN1PROD with BILLS
2 

•S 2974 IS

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


srobinson on DSK4SPTVN1PROD with BILLS
**Exhibit 32.2**

** **

**Certification ofQuarterly Report**

 

I, Michael K. Jackson,Corporate Controller and Chief Accounting Officer of NeoRx Corporation (the“Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,18 U.S.C. 1350 that:

 

a.               theQuarterly Report on Form 10-Q for the quarter ended June 30, 2004 (the“Report”) fully complies with the requirements of Section 13(a) or 15(d) of theSecurities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

 

b.              theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 

 
| Date:  |  August 9, 2004 | By:                 | /s/ MICHAEL  K. JACKSON |   |
|--------|----------------------|---------------------|-------------------------|--------|
|   |                 | Michael K.  Jackson |

 

----
EXHIBIT
32.1




CERTIFICATION
PURSUANT TO


18
U.S.C. SECTION 1350


AS
ADOPTED PURSUANT TO





SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Global Clean Energy, Inc. (the
“Company”) on Form 10-Q for the period ended March 31, 2010 as filed with the
Securities and Exchange Commission on May 17, 2010 (the “Report”), the
undersigned, in the capacity and on the date indicated below, hereby certifies
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:





1. The
Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended; and





2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operation of the Company.






Date:  May
      17, 2010
            /s/
      Earl AzimovEarl
      Azimov, President & Chief Executive Officer
Exhibit 31
                                  ----------


                                 CERTIFICATION
                                 -------------

        I, Steve Bailey, certify that:

        1. I have reviewed this annual report on Form 10-K, and all reports on
        Form 8-K containing distribution and servicing reports filed in respect
        of periods included in the year covered by this annual report, of CWABS
        Revolving Home Equity Loan Trust, Series 2004-O;

        2. Based on my knowledge, the information in these reports, taken as a
        whole, does not contain any untrue statement of a material fact or omit
        to state a material fact necessary to make the statements made, in light
        of the circumstances under which such statements were made, not
        misleading as of the last day of the period covered by this annual
        report;

        3. Based on my knowledge, the distribution or servicing information
        required to be provided to the trustee by the master servicer under the
        pooling and servicing, or similar, agreement, for inclusion in these
        reports is included in these reports;

        4. I am responsible for reviewing the activities performed by the master
        servicer under the pooling and servicing, or similar, agreement and
        based upon my knowledge and the annual compliance review required under
        that agreement, and except as disclosed in the reports, the master
        servicer has fulfilled its obligations under that agreement; and

        5. The reports disclose all significant deficiencies relating to the
        master servicer's compliance with the minimum servicing standards based
        upon the report provided by an independent public accountant, after
        conducting a review in compliance with the Uniform Single Attestation
        Program for Mortgage Bankers or similar procedure, as set forth in the
        pooling and servicing, or similar, agreement, that is included in these
        reports.

        In giving the certifications above, I have reasonably relied on
        information provided to me by the following unaffiliated parties:
        JPMorgan Chase Bank, N.A., as indenture trustee.

        Date: March 30, 2005

                              /s/ Steve Bailey
                                  -----------------
                                  Steve Bailey
                                  Senior Managing Director
EX-10.III



 Exhibit (10)(iii) 
 COOPER TIRE & RUBBER COMPANY 
 Written Description of Changes to
Independent Director Compensation and Stock Ownership Guidelines 
 (as approved by the Board of Directors on August 3, 2011)

 Cash Compensation (effective October 1, 2011): 
 Annual Retainer: $80,000 
 Annual Fees for Committee Chairs and Lead Director: 

Audit Committee Chair: $15,000 
 Compensation Committee Chair: $10,000 
 Nominating and Governance Committee
Chair: $10,000 
 Lead Director: $15,000 
 Equity Compensation (effective at 2012 Annual Meeting): 
 Annual Phantom Stock
Grant: $100,000 
 Stock Ownership Guidelines (effective immediately): 

Amount: 15,000 shares 
 Time for new
Director to reach: 5 years 

  
 1